Back to results

CompletedPhase 2

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

NCT00712881

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Teva Investigational Site 16

Kufstein, Austria

+21 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2008-10-13
Enrollment: 126 participants
Sponsor: Cephalon, Inc.
Purpose: treatment

Locations (22)

Teva Investigational Site 16Kufstein, Austria
Teva Investigational Site 15Vienna, Austria
Teva Investigational Site 9Brussels, Belgium
Teva Investigational Site 29Yvoir, Belgium
Teva Investigational Site 4Clichy, France
Teva Investigational Site 5Nancy, France
Teva Investigational Site 33Reims, France
Teva Investigational Site 8Vandœuvre-lès-Nancy, France
Teva Investigational Site 30Aachen, Germany
Teva Investigational Site 11Düsseldorf, Germany
Teva Investigational Site 25Düsseldorf, Germany
Teva Investigational Site 32Essen, Germany
Teva Investigational Site 34Loerrach, Germany
Teva Investigational Site 14München, Germany
Teva Investigational Site 27München, Germany
Teva Investigational Site 20Naples, Italy
Teva Investigational Site 23Roma, Italy
Teva Investigational Site 21Verona, Italy
Teva Investigational Site 26Barcelona, Spain
Teva Investigational Site 3Barcelona, Spain
Teva Investigational Site 1Lleida, Spain
Teva Investigational Site 2Zaragoza, Spain

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer — TrialFind